Boehringer Ingelheim Joins The Corporate Venture Party
This article was originally published in Start Up
Executive Summary
In late March, Boehringer Ingelheim GMBH formally unveiled its $134 million corporate venture fund, a strategically-focused effort that will invest in areas believed to be important to the privately-held German pharma's future growth, including RNA silencing, stem cells, and next generation vaccine, protein, and antibody technologies.
You may also be interested in...
Boehringer Ingelheim Shrugs Off Patent Cliff, Returns To Sales Growth
Germany's Boehringer Ingelheim returns to sales growth and looks to Phase III hepatitis C and oncology products to provide long-term growth.
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.
Merck's Capital Idea: Industry's Latest Push to Strengthen VC Ties
IN an effort to forge earlier and stronger ties to venture-backed biotechs, the new Merck Research Venture Fund illustrates the lure -- and the limitations -- of strategic pharma-VC relationships. Merck has endowed the MRVF with $250 million and the fund will make a series of investments in life science venture capital firms around the globe. Simultaneously it has also staked a second fund, the Global Health Innovation Fund, with an additional $250 million to invest in later-stage companies outside of the drug area.